

A THREE-STAGE BLENDED LEARNING PROGRAMME IN THE ATMP DEVELOPMENT

Dunja Urbančič - University of Ljubljana, Faculty of Pharmacy, Askerceva 7, SI-1000 Ljubljana, Slovenia



Next Generation of Advanced Therapies' Specialists

INTRODUCTION

Advanced therapy medicinal products (ATMPs):

- promise for the long-term management and cure of diseases
- the translation from research into patient benefit faces many challenges and requires the involvement of many stakeholders

Erasmus+ ADVANCE:

- 30-month training project
- supported by Erasmus+ Programme of the EU

METHOD

The core target group:

- early-career biomedical academics (PhDs, Postdocs)
- doctors in training
- clinicians
- scientists

elevate

• SME-based professionals

The three-stage blended learning programme:

- online course for teaching "basic" scientific knowledge
 webinars for in-depth scientific knowledge and skills, combined with career coaching
- 3. face-to-face workshops for training transversal skills and competences

AIM/S

The overall objective of the project is to develop a learning programme to develop a holistic vision of the complex processes and translate scientific advances into patient-oriented standards of care.

Both the webinars and the online course will be free of charge and available to a broad audience. The three curricula (1-3) will be complemented by digital credentials and a sustainability plan.

ENVISAGED RESULTS

The programme aims to have an impact on:

- enhancing the quality of knowledge
- transversal skills and competences trained and relevant for the biomedical labour market
- increasing the participants' employability in the field
- fostering the interaction between innovative research and development and education

Figure: A schematic representation of the project structure and predicted educational outreach



Successful implementation of curricula and sustainability-oriented design of the project anticipates long-term benefits in terms of improvements in public health due to better trained professionals who will drive effective and accelerated ATMP development and offer safe and affordable treatments for patients with high unmet medical needs.







(U LEUVE



Sio

clus

O

This project receives funding from the European Union's Erasmus Plus programme under grant agreement 2019-1-NL01-KA203-060286. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therei

